Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac + paracetamol + caffeine
- Development stage
- Unknown
- Lead developer
- Bhumi Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dignac Strong is a fixed-dose combination analgesic product developed and marketed by Bhumi Pharmaceuticals. It contains diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), paracetamol (acetaminophen), an analgesic and antipyretic, and caffeine, a methylxanthine that acts as an analgesic adjuvant. The combination is designed to provide synergistic pain relief by targeting multiple pathways: diclofenac and paracetamol inhibit prostaglandin synthesis via cyclooxygenase (COX) inhibition, while caffeine acts as an adenosine receptor antagonist to enhance the efficacy of the analgesics and provide a faster onset of action. It is primarily indicated for the treatment of acute pain, musculoskeletal disorders, and inflammatory conditions.
- Brand names
- Dignac Strong
- Other names
- Diclofenac/Paracetamol/Caffeine tablets
02
Targets
ADORA2A (Adenosine A₂A Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADORA1 (Adenosine receptor A1 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on diclofenac + paracetamol + caffeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac + paracetamol + caffeine.